Logo image of NKTX

NKARTA INC (NKTX) Stock Fundamental Analysis

NASDAQ:NKTX - US65487U1088 - Common Stock

2.2 USD
-0.17 (-7.17%)
Last: 8/25/2025, 7:16:32 PM
2.23 USD
+0.03 (+1.36%)
After Hours: 8/25/2025, 7:16:32 PM
Fundamental Rating

3

NKTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 547 industry peers in the Biotechnology industry. While NKTX has a great health rating, there are worries on its profitability. NKTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NKTX had negative earnings in the past year.
In the past year NKTX has reported a negative cash flow from operations.
NKTX had negative earnings in each of the past 5 years.
In the past 5 years NKTX always reported negative operating cash flow.
NKTX Yearly Net Income VS EBIT VS OCF VS FCFNKTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

NKTX has a Return On Assets of -23.64%. This is in the better half of the industry: NKTX outperforms 74.41% of its industry peers.
NKTX has a Return On Equity of -29.37%. This is in the better half of the industry: NKTX outperforms 77.70% of its industry peers.
Industry RankSector Rank
ROA -23.64%
ROE -29.37%
ROIC N/A
ROA(3y)-25.65%
ROA(5y)-27.09%
ROE(3y)-33.49%
ROE(5y)-32.64%
ROIC(3y)N/A
ROIC(5y)N/A
NKTX Yearly ROA, ROE, ROICNKTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

NKTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NKTX Yearly Profit, Operating, Gross MarginsNKTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, NKTX has more shares outstanding
The number of shares outstanding for NKTX has been increased compared to 5 years ago.
NKTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NKTX Yearly Shares OutstandingNKTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
NKTX Yearly Total Debt VS Total AssetsNKTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -0.90, we must say that NKTX is in the distress zone and has some risk of bankruptcy.
NKTX has a Altman-Z score (-0.90) which is in line with its industry peers.
There is no outstanding debt for NKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.9
ROIC/WACCN/A
WACCN/A
NKTX Yearly LT Debt VS Equity VS FCFNKTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

NKTX has a Current Ratio of 14.48. This indicates that NKTX is financially healthy and has no problem in meeting its short term obligations.
NKTX has a Current ratio of 14.48. This is amongst the best in the industry. NKTX outperforms 89.21% of its industry peers.
NKTX has a Quick Ratio of 14.48. This indicates that NKTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 14.48, NKTX belongs to the top of the industry, outperforming 89.58% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.48
Quick Ratio 14.48
NKTX Yearly Current Assets VS Current LiabilitesNKTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.37% over the past year.
EPS 1Y (TTM)26.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.82%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 7.85% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y14.9%
EPS Next 2Y8.53%
EPS Next 3Y-1.6%
EPS Next 5Y7.85%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NKTX Yearly Revenue VS EstimatesNKTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2027 2028 2029 2030 2031 2032 100M 200M 300M
NKTX Yearly EPS VS EstimatesNKTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NKTX. In the last year negative earnings were reported.
Also next year NKTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NKTX Price Earnings VS Forward Price EarningsNKTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NKTX Per share dataNKTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.53%
EPS Next 3Y-1.6%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NKTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NKARTA INC

NASDAQ:NKTX (8/25/2025, 7:16:32 PM)

After market: 2.23 +0.03 (+1.36%)

2.2

-0.17 (-7.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners90.35%
Inst Owner Change-3.7%
Ins Owners0.4%
Ins Owner Change-0.05%
Market Cap156.24M
Analysts83.08
Price Target12.65 (475%)
Short Float %12.18%
Short Ratio14.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.54%
Min EPS beat(2)4.19%
Max EPS beat(2)16.89%
EPS beat(4)3
Avg EPS beat(4)10.56%
Min EPS beat(4)-4.75%
Max EPS beat(4)25.93%
EPS beat(8)6
Avg EPS beat(8)10.47%
EPS beat(12)8
Avg EPS beat(12)8.17%
EPS beat(16)9
Avg EPS beat(16)6.83%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.12%
PT rev (3m)-10.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)5.78%
EPS NY rev (3m)5.78%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-1.48
EYN/A
EPS(NY)-1.36
Fwd EYN/A
FCF(TTM)-1.48
FCFYN/A
OCF(TTM)-1.41
OCFYN/A
SpS0
BVpS5.33
TBVpS5.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.64%
ROE -29.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.65%
ROA(5y)-27.09%
ROE(3y)-33.49%
ROE(5y)-32.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 51.65%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.48
Quick Ratio 14.48
Altman-Z -0.9
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)770.74%
Cap/Depr(5y)709.73%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.82%
EPS Next Y14.9%
EPS Next 2Y8.53%
EPS Next 3Y-1.6%
EPS Next 5Y7.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.72%
EBIT Next 3Y4.08%
EBIT Next 5Y2.85%
FCF growth 1Y4.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68.58%
OCF growth 3YN/A
OCF growth 5YN/A